Novigenix | WebDisclosure

Basculer en Français

9472	Companies
185370	Keywords
117721	Articles
99262	Press releases

Home
Companies
Novigenix

PRESS RELEASE

published on 01/17/2024 at 08:00, 1 year 10 months ago

Revolutionizing Drug Development: Novigenix Unveils AI-Powered RNA Analysis for Immune Response Profiling
Novigenix, a leader in AI healthcare solutions, is launching LITOSeek™, a revolutionary innovation that utilizes advanced AI and RNA analysis to reshape cancer care and expedite drug development. Leveraging precision immunology, Novigenix is set to empower biopharma companies and transform cancer treatment paradigms, offering a breakthrough in personalized cancer treatment. With a team of over 20 Ph.D.-level scientists dedicated to advancing next-generation liquid biopsy solutions, Novigenix is at the forefront of pioneering precision immunology for superior patient outcomes.

Novigenix LITOSeek AI Healthcare Solutions Precision Immunology Cancer Care

Accesswire

Published on 12/05/2025 at 02:35, 4 hours 55 minutes ago

Future Fuels Initates Drill Permitting at Hornby; Marketing Update
Published on 12/05/2025 at 02:30, 5 hours ago

Klondike Gold Announces AGM Results
Published on 12/05/2025 at 01:00, 6 hours 30 minutes ago

BEACN Closes First Tranche of Non-Brokered Private Placement
Published on 12/04/2025 at 23:05, 8 hours 25 minutes ago

BlackBerry to Announce Third Quarter Fiscal Year 2026 Results on December 18, 2025
Published on 12/04/2025 at 23:00, 8 hours 30 minutes ago

NXT Energy Solutions Completes Data Acquisition for SFD Survey

View all ACCESSWIRE

EQS Group

Published on 12/05/2025 at 07:00, 29 minutes ago

Swiss Re targets a net income of USD 4.5 billion in 2026; refreshed strategy to strengthen core business
Published on 12/05/2025 at 03:30, 3 hours 59 minutes ago

CGTN: What makes cooperation between China and France a two-way success
Published on 12/04/2025 at 23:50, 7 hours 39 minutes ago

EQS-Adhoc: Dexus Finance Pty Limited: Dexus prices A$500 million of subordinated notes
Published on 12/04/2025 at 20:25, 11 hours 4 minutes ago

Newmark Appoints Globally Recognized Real Estate Executive Peter Trollope to Lead Occupier Solutions
Published on 12/04/2025 at 20:15, 11 hours 14 minutes ago

Galimedix Therapeutics presents compelling Phase 1 study results showing excellent safety and pharmacokinetics with oral small molecule GAL-101 at CTAD 2025

Les Echos

Published on 12/04/2025 at 18:14, 13 hours 15 minutes ago

Résiliation d'une convention conclue entre actionnaires
Published on 12/04/2025 at 18:00, 13 hours 30 minutes ago

Informations relatives au nombre total de droits de vote et d’actions composant le capital social au 28 novembre 2025
Published on 12/04/2025 at 18:00, 13 hours 30 minutes ago

Information concerning the total number of voting rights and shares in the share capital as of November 28, 2025
Published on 12/04/2025 at 17:45, 13 hours 45 minutes ago

Informations relatives au nombre total de droits de vote et d’actions
Published on 12/04/2025 at 17:45, 13 hours 45 minutes ago

MONTHLY INFORMATION RELATING TO THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES MAKING UP THE SHARE CAPITAL

View all LES ECHOS COMFI WIRE